Verrica Pharmaceuticals Inc. Stock Analysis & AI Score
Verrica Pharmaceuticals Inc. (VRCA) has an ST Score of 42.4 (C), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Buy with a $9.00 price target (+106.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Verrica Pharmaceuticals Inc. (VRCA) has an ST Score of 42.4 (C), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Buy with a $9.00 price target (+106.4% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityF
All factor grades
- ForecastA
- GrowthB
- ValuationC+
- MomentumC+
- Financial StrengthD-
- ProfitabilityF
- Piotroski4/9
Contact
VRCA stock: frequently asked questions
What is VRCA's ST Score?
Verrica Pharmaceuticals Inc. (VRCA) has an ST Score of 42.4 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is VRCA a buy, hold, or sell?
Analysts rate VRCA a Buy, with a price target of $9.00 (+106.4% vs the current price). Our ST Score grades it C (42.4/100). The ST Score is a data-driven signal, not a recommendation.
What are VRCA's factor grades?
Valuation C+, Profitability F, Financial Strength D-, Momentum C+, Growth B, Forecast A.
What is VRCA's valuation grade?
Verrica Pharmaceuticals Inc. (VRCA) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is VRCA's growth grade?
Verrica Pharmaceuticals Inc. (VRCA) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is VRCA's profitability grade?
Verrica Pharmaceuticals Inc. (VRCA) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is VRCA's financial strength grade?
Verrica Pharmaceuticals Inc. (VRCA) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for VRCA?
The average analyst price target for Verrica Pharmaceuticals Inc. (VRCA) is $9.00 from 10 analysts, which is +106.4% versus the recent price of $4.36.
What is VRCA's Piotroski score?
Verrica Pharmaceuticals Inc. (VRCA) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.